Skip to content

Efficacy of Virtual Reality Reminiscence Therapy in Nursing Home Residents With Alzheimer's Disease or Related Diseases

Efficacy of Virtual Reality Reminiscence Therapy in Nursing Home Residents With Alzheimer's Disease or Related Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06960915
Acronym
ReminiSOMME
Enrollment
50
Registered
2025-05-07
Start date
2025-10-10
Completion date
2027-03-01
Last updated
2026-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease or Related Diseases, Crossover Study, Nursing Home, Reminiscence Therapy, Virtual Reality

Keywords

Virtual reality, Reminiscence therapy, Nursing home, Alzheimer's disease or related diseases, crossover study

Brief summary

This project provides the easiest possible access to heritage elements that older persons with Alzheimer's disease or related diseases knew well but to which they no longer have access due to the motor and functional dependencies they present. It will strengthen the possibilities of reminiscence by using, rather than the usual supports, virtual reality technology to reinforce the immersion effect. It will involve carrying out virtual reality reminiscence workshops intended for residents in nursing home with Alzheimer's disease or related diseases and allowing them to explore the heritage of towns and villages in the Somme region thanks to these innovative solutions. The aim of this project is to reduce behavioral disorders and improve their quality of life.

Interventions

DEVICEclassic reminiscence workshops

It will be compared to classic reminiscence workshops in which the organizer will propose to discuss memories and past experiences using photographs, objects or music in the control arm.

DEVICEimmersive virtual reality

The research procedure will be the realization of reminiscence workshops in immersive virtual reality. The residents will be equipped with a virtual reality headset where they will enjoy 360° panoramas that will immerse them in the heart of villages in the Amiens basin and in particular their village based on 3 to 5 images per village: church square, village square, town hall, emblematic places, etc.

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Residents of the long-term care facilities of the Amiens-Picardie University Hospital, * Residents with mild to moderate Alzheimer's disease or related diseases, i.e. with an MMSE ≥ 10, * Residents or their legal representative agreeing to participate in the study.

Exclusion criteria

* Non-residents of the long-term care facilities of the Amiens-Picardie University Hospital, * Residents with an MMS \< 10, * Residents or their legal representative refusing to participate in the study, * Residents in terminal palliative care, * Residents with disruptive behavioral disorders.

Design outcomes

Primary

MeasureTime frameDescription
Reduced behavioral problem frequency in immersive virtual reality group1 yearEfficacy in reducing behavioral problems will be assessed using the sum of scores on the NPI-ES anxiety, depression, and apathy subscales.

Secondary

MeasureTime frameDescription
Improved quality of life in the immersive virtual reality group1 yearimproving the quality of life will be assessed using a quality of life scale developed for patients with Alzheimer's disease or related diseases, the QOL-AD scale validated in French. The QOL-AD is administered in interview format to individuals with dementia, following the instructions below. Scoring instructions for QOL-AD: Points are assigned to each item as follows: poor = 1, fair = 2, good = 3, excellent = 4. The total score is the sum of all 13 items.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026